Platinum-based adjuvant therapy was efficient for triple-negative breast cancer: a meta-analysis from randomized controlled trials

Platinum-based adjuvant therapy was efficient for triple-negative breast cancer: a meta-analysis from randomized controlled trials

ABSTRACTTriple-negative breast cancer (TNBC) is the most aggressive breast cancer. Neoadjuvant chemotherapy was widely accepted for treating TNBC. This systematic review and meta-analysis aimed to evaluate the efficacy, safety, and survival benefit of platinum-based adjuvant therapy (PBAT) in treati...

Full description

Bibliographic Details
Main Authors: Kaigang Xie, Xuanlei Ren, Xiaoming Hong, Shuiyin Zhu, Dongjie Wang, Xiaoming Ye, Xiaoting Ren
Format: Article
Language:English
Published: Taylor & Francis Group 2022-06-01
Series:Bioengineered
Subjects:
triple-negative breast cancer
platinum
neoadjuvant therapy
survival
Online Access:https://www.tandfonline.com/doi/10.1080/21655979.2022.2115616

Similar Items

Similar Items